Relevant prognostic factors influencing outcome of patients after surgical resection of distal cholangiocarcinoma

Oliver Beetz 1†, Michael Klein 1†, Harald Schrem 1,2, Jill Gwiasda 2, Florian W. R. Vondran 1, Felix Oldhafer 1, Sebastian Cammann 1, Jürgen Klempnauer 1, Karl J. Oldhafer 3 and Moritz Kleine 1*

Abstract

Background: Distal cholangiocarcinoma (DCC) is a rare but over the last decade increasing malignancy and is associated with poor prognosis. According to the present knowledge curative surgery is the only chance for long-term survival. This study was performed to evaluate prognostic factors for the outcome of patients undergoing curative surgery for distal cholangiocarcinoma.

Methods: 75 patients who underwent surgery between January 2000 and December 2014 for DCC in curative intention were analysed retrospectively. Potential prognostic factors for survival were investigated including the extent of surgery using purposeful selection of covariates in multivariable Cox regression modeling.

Results: Preoperative biliary stenting (Hazard ratio (HR): 2.530; 95%-CI: 1.146–6.464, \( p = 0.020 \)), the extent of surgery in case of positive histological venous invasion (HR: 1.209; 95%-CI: 1.017–1.410, \( p = 0.032 \)), lymph node staging (HR: 2.183; 95%-CI: 1.250–3.841, \( p = 0.006 \)), perineural invasion (HR: 2.118; 95%-CI: 1.147–4.054, \( p = 0.016 \)) and postoperative complications graded in points according to Clavien-Dindo (HR: 1.395; 95%-CI: 1.148–1.699, \( p = 0.001 \)) were indentified as independent significant risk factors for survival. Patients receiving preoperative biliary stenting showed prolonged duration between onset of symptoms and date of operation (\( p = 0.048 \)).

Conclusions: Preoperative biliary stenting reduces survival possibly due to delayed surgery. The extent of surgery is not an independent risk factor for survival except for patients with concomitant histological venous invasion. Oncological factors and postoperative surgical complications are independent prognostic factors for survival.

Keywords: Distal bile duct cancer, Extended surgery, Venous invasion, Preoperative biliary stenting

Background

Cholangiocarcinoma is a malignant disease with poor prognosis and occurs with an incidence of 1.3 to 3.4 cases per 100,000 in Western countries [1].

The primary location of the carcinoma in reference to the biliary tract influences clinical manifestation and therapy. Therefore they are classified into intrahepatic, proximal extrahepatic and distal extrahepatic cholangiocarcinomas (DCC) [2].

DCC constitute up to 20–30% of all cholangiocarcinomas and are located between the cystic duct entry into the main hepatic duct and the Ampulla of Vater. Clinical symptoms comprise painless jaundice and/or weight loss [3].

Curative surgery is the only chance for long-term survival [3–9]. Palliative chemotherapy can achieve median survival rates of 8.1 to 11.7 months [10].

Apart from negative lymph node status, a tumor-free resection margin has been reported to have crucial impact on disease free survival [4, 5, 11, 12]. Nevertheless, tumor stage-specific surgical strategies have not been clearly defined. Some centers perform segmental bile duct resections when the tumor is small and located in the middle segment of the extrahepatic bile duct. Major surgery
including partial pancreaticoduodenectomy is necessary to achieve tumor-free resection margins in the majority of cases [6, 13]. Some patients present with advanced tumors with additional infiltration of central bile ducts on one side of the liver or local infiltration of the portal vein. For these patients extended pancreatic resection with en-bloc portal vein resection or additional resection of proximal extrahepatic bile ducts might be necessary to achieve tumor-free resection margins [8, 14, 15].

Most published data describe inhomogeneous patient groups with respect to the primary location of biliary tract carcinoma [3–9]. The objective of this study was to evaluate the outcome of surgery in patients with DCC following resection in curative intent. In this context, the focus was put on the extent of surgical resection to clarify the role of organ preserving resection and extended surgery, including additional resection of the proximal extrahepatic bile ducts and/or partial resection of the portal vein.

Methods

Study cohort and investigated variables

This is a retrospective analysis of 75 patients with DCC undergoing surgical resection at the Department of General, Visceral and Transplant Surgery, Hannover Medical School, Germany between January 2000 and December 2014. Median overall survival follow-up was 19 months (range: 0–178 months). The clinical and histopathological variables of the study cohort are summarized in Table 1.

Inclusion criteria

Included were all resections for histologically confirmed DCC (n = 75) in patients older than 18 years of age. No exclusion criteria were defined.

Definition of variables and surgical treatment

Due to a lack of histological differentiation between proximal and distal extrahepatic cholangiocarcinoma the diagnosis was defined by the location of the primary tumor distal to the confluence of the cystic duct and the common bile duct. According to intraoperative tumor extent patients either received local excisions of the extrahepatic bile ducts (including lymphadenectomy of the hepato-duodenal ligament), partial pancreaticoduodenectomy or pancreatic resection with additional partial resection of perihilar bile ducts, portal vein or liver. Oncological lymphadenectomy along the hepatic artery and down to the celiac trunk was performed in all patients receiving pancreatic resections. The extent of surgery was then graded in points as displayed in Table 1.

Histopathology

DCC was histopathologically confirmed by paraffin embedded and haematoxylin and eosin (HE), Periodic acid–Schiff (PAS) and elastic Van Gieson's (EVG) stained slides. In some cases additional immunohistochemical staining for IgG4 was performed. Tumors were classified according to the classification system proposed by the International Union Against Cancer [16].

Study end-points

The primary study endpoints were overall survival (OS) and postoperative complications graded according to the Clavien-Dindo Classification of Surgical Complications [17]. Secondary endpoints were length of intensive care unit (ICU) and hospital stay.

Statistical methods

The influence of nominal and ordinal variables on binary study endpoints were analysed with chi-squared test and Fisher's exact test while the influence of continuous variables on these endpoints was analysed with univariable logistic regression. Median and mean values between groups were compared with the Mann-Whitney U test. Ordinal regression and Kaplan-Meier analyses with the Log-rank test were performed where appropriate.

Risk factors for patient survival were initially analysed with univariable Cox regression analysis. Identification of independent risk factors influencing overall patient survival was achieved by developing a multivariable Cox regression model including potential multiplicative or additional factor interactions based on backwards likelihood elimination followed by forward likelihood inclusion of variables as has been proposed by Hosmer et al. and has been applied and published recently by our workgroup [18, 19]. The collected data was implemented and analysed using SPSS statistical software (version 23; SPSS Inc.; IBM corporation, Somers, NY) and JMP statistical software (version 13; SAS Institute; Cary, NC).

Results

Epidemiology and preoperative course

The median age of the study population at time of the operation was 67 years (33–87 years) and 82.7% (n = 62) of the patients were male (Table 1).

Symptoms were jaundice, epigastric pain, gastroesophageal reflux, weight loss, lack of appetite and nausea.

The standard preoperative assessment and staging included endoscopic retrograde cholangiopancreatography (ERCP) received by 88.0% of the patients, ultrasound (78.7%) and computed tomography (CT) (74.7%) or magnetic resonance imaging (17.3%). Location of the tumor was primarily defined by ERCP. The extent of tumor was anticipated mainly according to CT, however CT scans could not identify any tumor mass in 22 patients. Five of these patients underwent additional MR
Table 1: Descriptive statistics of the investigated cohort of 75 patients undergoing surgery for distal cholangiocarcinoma

| Variables                      | n (%) | Mean, Median (min-max) | Missing values n(%) |
|--------------------------------|-------|------------------------|---------------------|
| Age (years)                    | n.a.  | 65.2, 67 (33–87)       | 0 (0.0%)            |
| Male gender                    | 62 (82.7%) | n.a.                    | 0 (0.0%)            |
| Preoperative biliary stent     | 58 (77.3%) | n.a.                    | 5 (6.7%)            |
| Extent of surgery              |       |                        |                     |
| Local bile duct excision w/o hilus | 1 point | 7 (9.3%)                | 0 (0.0%)            |
| Local bile duct excision with hilus | 2 points | 3 (4.0%)                |                     |
| Pancreatoduodenectomy          | 3 points | 54 (72.0%)              |                     |
| with hilus resection           | 4 points | 5 (6.7%)                |                     |
| with portal vein resection     | 5 points | 6 (8.0%)                |                     |
| Duration of operation (min)    | n.a.  | 238.1, 230 (130–490)    | 0 (0.0%)            |
| Grading                        |       |                        |                     |
| G1                             | 1 point | 2 (2.7%)                | 2.3, 2 (1–3)        | 0 (0.0%)            |
| G2                             | 2 points | 51 (68.0%)              |                     |
| G3                             | 3 points | 22 (29.3%)              |                     |
| pT stages                      |       |                        |                     |
| pT1                            | 1 point | 4 (5.3%)                | 2.6, 3 (1–4)        | 0 (0.0%)            |
| pT2                            | 2 points | 28 (37.3%)              |                     |
| pT3                            | 3 points | 36 (48%)                |                     |
| pT4                            | 4 points | 7 (9.3%)                |                     |
| pN stages                      |       |                        |                     |
| pN0                            | 0 points | 34 (45.3%)              | 0.6, 1 (0–2)        | 0 (0.0%)            |
| pN1                            | 1 point | 39 (52%)                |                     |
| pN2                            | 2 point | 2 (2.7%)                |                     |
| M1 stage                       |       |                        |                     |
| R0 resection                   | 65 (86.7%) | n.a.                    | 1 (1.3%)            |
| Perineural invasion            | 46 (62.2%) | n.a.                    | 1 (1.3%)            |
| Venous invasion                | 16 (21.6%) | n.a.                    |                     |
| Lymph vessel invasion          | 22 (29.7%) | n.a.                    | 1 (1.3%)            |
| UICC stages                    |       |                        |                     |
| UICC Ia                        | 1 point | 4 (5.3%)                | 3.6, 4 (1–6)        | 0 (0.0%)            |
| UICC Ib                        | 2 points | 15 (20.0%)              |                     |
| UICC IIA                       | 3 points | 9 (12.0%)               |                     |
| UICC IIB                       | 4 points | 32 (42.7%)              |                     |
| UICC III                       | 5 points | 9 (12.0%)               |                     |
| UICC IV                        | 6 points | 6 (8.0%)                |                     |
| Grading of complications       |       |                        |                     |
| Clavien-Dindo Grade 0          | 0 points | 25 (33.3%)              | 1.8, 1 (0–5)        | 2 (2.7%)            |
| Clavien-Dindo Grade I          | 1 point | 15 (20.0%)              |                     |
| Clavien-Dindo Grade II         | 2 points | 7 (9.3%)                |                     |
| Clavien-Dindo Grade III        | 3 points | 11 (14.7%)              |                     |
| Clavien-Dindo Grade IV         | 4 points | 9 (12.0%)               |                     |
| Clavien-Dindo Grade V          | 5 points | 6 (8.0%)                |                     |
| Complications leading to surgical intervention | 19 (26.0%) | n.a.                    | 2 (2.7%)            |
| Observed overall survival in months | n.a. | 29.1, 19 (0–145)       | 2 (2.7%)            |
| Observed disease-free survival in months | n.a. | 20.8, 13 (3–143)       | 47 (62.7%)          |
| Hospital mortality             | 6 (8.0%) | n.a.                    | 1 (1.3%)            |
| Hospital stay in days          | n.a.  | 29.8, 25 (7–102)       | 2 (2.7%)            |
| ICU stay in days               |       | 7.3, 3 (1–94)          | 17 (22.7%)          |
| Days between onset of symptoms and date of surgery | n.a. | 54.9, 34 (8–334)       | 36 (48.0%)          |

Table 1: Shown are descriptive statistics of the investigated cohort of 75 patients. The extent of surgery was scaled from 1 (local bile duct excision without resection of the perihilar bile ducts) to 5 points (pancreatoduodenectomy including partial portal vein resection). This scale was used to calculate the variable “extent of surgery graded in points multiplied by histological venous invasion” as displayed in Table 2.
tomography for verification of tumor extent with successful detection of the lesions in two patients.

Biopsies were performed in 33 patients (44.0%) whereas brush cytologies were performed in 39 patients (52.0%). Hereby the diagnosis was verified in 49.3% of the patients.

Preoperative biliary stenting via ERCP (internal drainage) as a consequence of relevant cholestasis was performed in 77.3% of the patients (n = 58). Percutaneous Transhepatic Cholangio-Drainage (PTCD) was not required in our patient collective. Patients receiving biliary stenting prior to operation showed significantly prolonged duration between onset of symptoms and operation (p = 0.048). Preoperative biliary stenting was found to be an independent risk factor for worse overall survival in multivariable Cox regression analysis (HR: 2.530; 95%-CI: 1.146–6.464, p = 0.020) (Table 2) (Fig. 1a).

The median time interval between onset of symptoms and operation was 34 days (Table 1).

Surgical results
In ten patients local excisions of the extrahepatic bile ducts were performed which included lymphadenectomy of the hepato-duodenal ligament representing a collective ducts were performed which included lymphadenectomy.

In ten patients local excisions of the extrahepatic bile ducts were performed which included lymphadenectomy. Peroperative Transhepatic Cholangio-Drainage (PTCD) was not required in our patient collective. Patients receiving biliary stenting prior to operation showed significantly prolonged duration between onset of symptoms and operation (p = 0.048). Preoperative biliary stenting was found to be an independent risk factor for worse overall survival in multivariable Cox regression analysis (HR: 2.530; 95%-CI: 1.146–6.464, p = 0.020) (Table 2) (Fig. 1a).

The median time interval between onset of symptoms and operation was 34 days (Table 1).

Histopathological results
Low T-staging depended significantly on a short time period between first symptoms and operation (p = 0.021, ordinal regression). However, delayed surgery did not significantly influence tumor stage according to UICC (p = 0.160, ordinal regression) or the success of the operation defined as tumor-free resection margins (Odds ratio (OR): 0.995; 95%-CI: 0.974–1.017, p = 0.006) (Fig. 1c).

Sensitive resection margins (R0) in final histology were achieved in 77.3% of the patients (n = 58). Percutaneous Transhepatic Cholangio-Drainage (PTCD) was not required in our patient collective. Patients receiving biliary stenting prior to operation showed significantly prolonged duration between onset of symptoms and operation (p = 0.048). Preoperative biliary stenting was found to be an independent risk factor for worse overall survival in multivariable Cox regression analysis (HR: 2.530; 95%-CI: 1.146–6.464, p = 0.020) (Table 2) (Fig. 1a).

The median time interval between onset of symptoms and operation was 34 days (Table 1).

Histopathological results
Low T-staging depended significantly on a short time period between first symptoms and operation (p = 0.021, ordinal regression). However, delayed surgery did not significantly influence tumor stage according to UICC (p = 0.160, ordinal regression) or the success of the operation defined as tumor-free resection margins (Odds ratio (OR): 0.995; 95%-CI: 0.974–1.017, p = 0.006) (Fig. 1c).

Histopathological results
Low T-staging depended significantly on a short time period between first symptoms and operation (p = 0.021, ordinal regression). However, delayed surgery did not significantly influence tumor stage according to UICC (p = 0.160, ordinal regression) or the success of the operation defined as tumor-free resection margins (Odds ratio (OR): 0.995; 95%-CI: 0.974–1.017, p = 0.006) (Fig. 1c).
Table 2: Shown are the uni- and multivariable Cox regression analysis to identify risk factors for overall survival.

| Variables (univariable Cox regression analysis) | HR    | 95%-CI   | p-value |
|------------------------------------------------|-------|----------|---------|
| Age (years)                                    | 1.005 | 0.980 – 1.032 | 0.713  |
| Male gender                                    | 0.791 | 0.431 – 1.569 | 0.482  |
| Preoperative biliary stent                     | 1.412 | 0.704 – 2.338 | 0.350  |
| Extent of surgery                              |       |           |         |
| Local bile duct excision w/o hilus             | 1.034 | 0.753 – 1.427 | 0.836  |
| Local bile duct excision with hilus            |       |           |         |
| Pancreaticoduodenectomy                         |       |           |         |
| with hilus resection                           | 0.439 | 0.132 – 1.081 | 0.077  |
| with portal vein resection                     |       |           |         |
| Preoperative biliary stent                     | 2.070 | 0.786 – 4.534 | 0.129  |
| Duration of operation (min)                    | 0.998 | 0.994 – 1.001 | 0.311  |
| Grading                                        |       |           |         |
| G1                                             | 1.638 | 0.921 – 2.863 | 0.092  |
| G2                                             |       |           |         |
| G3                                             |       |           |         |
| pT stages                                      |       |           |         |
| pT1                                            | 1.191 | 0.855 – 1.656 | 0.300  |
| pT2                                            |       |           |         |
| pT3                                            |       |           |         |
| pT4                                            | 4.048 | 0.642 – 2.562 | 0.048  |
| pN stages                                      |       |           |         |
| pN0                                            | 1.717 | 1.092 – 2.668 | 0.020  |
| pN1                                            |       |           |         |
| pN2                                            |       |           |         |
| M1 stage                                       | 1.913 | 1.110 – 3.397 | 0.019  |
| R0 resection                                   | 0.376 | 0.160 – 0.841 | 0.011  |
| Perineural invasion                            | 1.932 | 1.006 – 3.502 | 0.048  |
| Venous invasion                                | 1.094 | 0.490 – 2.470 | 0.769  |
| Lymph vessel invasion                          | 1.635 | 0.904 – 2.850 | 0.102  |
| UICC stages                                    |       |           |         |
| UICC Ia                                        | 1.119 | 0.931 – 1.346 | 0.230  |
| UICC Ib                                        |       |           |         |
| UICC IIA                                       |       |           |         |
| UICC IIB                                       |       |           |         |
| UICC III                                       |       |           |         |
| UICC IV                                        |       |           |         |
| Grading of complications                       |       |           |         |
| Clavien-Dindo Grade 0                          | 1.226 | 1.034 – 1.452 | 0.020  |
| Clavien-Dindo Grade I                          |       |           |         |
| Clavien-Dindo Grade II                         |       |           |         |
| Clavien-Dindo Grade III                        |       |           |         |
| Clavien-Dindo Grade IV                         |       |           |         |
| Clavien-Dindo Grade V                          |       |           |         |
| Complications leading to surgical intervention | 1.302 | 0.696 – 2.306 | 0.395  |
In 46 patients (62.2%) histopathological analysis revealed perineural invasion. Univariable (p = 0.019) and multivariable analysis (HR: 2.118; 95%-CI: 1.147–4.054, p = 0.016) identified perineural invasion as significant risk factor for overall survival (Fig. 1d).

Venous invasion was observed in 16 patients (21.6%) with significant influence on worse overall survival in univariable analysis (p = 0.048) (Fig. 1e). Further histopathological results and their influence on patient outcome are displayed in Tables 1 and 2.

**Postoperative course and complications**

Median postoperative hospital stay was 25 days including a median of 3 days in the ICU. Extended surgery did not significantly prolong postoperative hospital stay nor time spent in the ICU.

Fourty-five patients (60.0%) had complications with varying degrees of severity graded according to Clavien-Dindo (Tables 1 and 3). Univariable (p = 0.020) and multivariable analysis (HR: 1.395; 95%-CI: 1.148–1.699, p = 0.001) identified the grade of postoperative complications as significant risk factor for worse overall survival (Fig. 1f).

Patients undergoing different extents of surgery as stated above did not experience statistically significant differences regarding rate and severity of postoperative complications.

The most common complications were wound infections with a rate of 21.3%.

Type A pancreatic fistulas were not documented due to missing data on enzyme measurements from abdominal drains. Type B pancreatic fistulas were observed in ten patients (13.3%). Type C pancreatic fistulas were

---

**Table 2** Shown are the uni- and multivariable Cox regression analysis to identify risk factors for overall survival (Continued)

| Variables (univariable Cox regression analysis) | HR       | 95%-CI       | p-value |
|-----------------------------------------------|----------|--------------|---------|
| Preoperative biliary stenting                 | 2.530    | 1.146–6.464  | 0.020   |
| Venous invasion (yes=1, no=0) multiplied by Extent of surgery graded in points | 1.209    | 1.017–1.410  | 0.032   |
| Lymph node staging graded in points           | 2.183    | 1.250–3.841  | 0.006   |
| Perineural invasion                           | 2.118    | 1.147–4.054  | 0.016   |
| Complications graded by Clavien-Dindo         | 1.395    | 1.148–1.699  | 0.001   |

Univariable Cox regression analysis identified lymph node staging (N), perineural invasion, venous invasion and grading of complications according to Clavien-Dindo as significant risk factors for worse overall survival.

The final multivariable Cox regression model determined preoperative biliary stenting, the extent of surgery in case of positive histological venous invasion, lymph node staging and perineural invasion as well as postoperative complications graded in points according to Clavien-Dindo as independent significant risk factors for survival.

---

**Fig. 1** Survival (Kaplan-Meier) after resection of distal cholangiocarcinoma according to preoperative biliary stenting (a), extent of surgery (b), lymph node staging (c), perineural invasion (d), venous invasion (e) and postoperative complications graded by Clavien-Dindo (f). Shown are all risk factors that were significant in univariable or multivariable Cox regression analysis, respectively. Overall survival in months after resection of distal cholangiocarcinoma depending to the studied factors.
diagnosed in seven patients (9.3%) and total pancreatectomy was performed in six individuals (8.0%).

Eight patients (10.7%) suffered from insufficiency of the biliodigestive anastomosis.

Early mortality, defined as death in the first 30 post-operative days was 6.7% (n = 5). Causes of death were cardiac arrest due to cardiac infarction in one patient, sepsis and organ failure after total pancreatectomy due to insufficiency of the pancreatic anastomosis and arterial bleeding in two patients, and organ failure due to severe pneumonia in two further patients.

After local excision of the extrahepatic bile duct three of ten patients suffered from local tumor recurrence while another patient developed liver metastasis in the observation period. Patients undergoing standard pancreatic resection developed tumor recurrence in 21 documented cases ranging from local recurrence (n = 5), to lymph node, liver, bone and peritoneal metastases (n = 16). Three of eleven patients after extend pancreatic surgery suffered from local recurrence whereas two patients developed distant metastases in liver and peritoneum.

The rate of observed tumor recurrence was not significantly influenced by the extent of surgery.

The median overall survival was 19 months (0–145). Fifty-two (72.0%), 18 (30.0%) and 11 (22.0%) patients survived more than 1, 3 and 5 years, respectively. Thirteen patients (17.3%) were still alive at the time of data analysis.

### Table 3

| Complications                              | Number of patients (%) |
|--------------------------------------------|------------------------|
| Wound infection                            | 16 (21.3)              |
| Pancreatic fistula grade B                  | 10 (13.3)              |
| Insufficiency of biliodigestive anastomosis| 8 (10.7)               |
| Pancreatic fistula grade C                  | 7 (9.3)                |
| Death within 30 postoperative days         | 5 (6.7)                |
| Renal insufficiency                        | 5 (6.7)                |
| Delayed gastric emptying                   | 5 (6.7)                |
| Erosion haemorrhage                        | 4 (5.3)                |
| Acute confusional state                    | 3 (4.0)                |
| Pleural effusion                           | 3 (4.0)                |
| Pneumonia                                  | 2 (2.7)                |
| Cardiovascular events                      | 2 (2.7)                |
| Urinary tract infection                    | 1 (1.3)                |
| Hepatic insufficiency                      | 1 (1.3)                |
| Thrombosis of portal vein                 | 1 (1.3)                |
| Intrabdominal abscess                      | 1 (1.3)                |
| Postoperative bleeding                     | 1 (1.3)                |

Table 3: Number (and frequency) of complications in patients with distal cholangiocarcinoma after receiving surgical treatment

### Discussion

Due to the aforementioned comparatively low incidence of DCC among the general population, especially from Western countries, reports on outcome after surgery, of large patient collectives, are scarce. This data from a single high-volume center was analysed to identify prognostic factors for unfavourable patient outcome.

Interestingly no published data investigated preoperative stenting in patients with DCC and its impact on survival yet. In multivariable analysis we identified preoperative stenting as strongest risk factor for survival. A significantly longer duration between first symptoms and surgery in these patients could provide a clinically plausible explanation for the inferior outcome (Table 2). A prospective trial aiming to elucidate the role of preoperative biliary stenting in patients with pancreatic head cancer showed a significantly higher rate of complications after preoperative stenting [20]. So far similar observations have not yet been reported for DCC. The current study did not find a significant influence of biliary stenting on the rate or severity of postoperative complications. Nonetheless, we are well aware that preoperative conditions, which were not analysed in the current study, like cholangitis or severe biliary obstruction which require prolonged biliary drainage could be an explanation for the inferior postoperative outcome [21].

Survival after surgical treatment in the current study was similar to several previous studies [22–28].

Reported outcomes of patients with DCC after extended pancreatic surgery are extremely scarce. Solely Courtin-Tanguy et al. investigated extended surgery for treatment of DCC and found that combined organ resection was an independent risk factor for worse survival [29]. Interestingly, the present study showed that extended pancreatic resection was not significantly associated with inferior survival except in case of concomitant histological venous invasion as displayed by the identified interaction variable. Previous studies on risk factors for survival have not taken possible multiplicative factor interactions into account [28, 30]. The approach to multivariable Cox regression in this study deploys the previously published methodology for the detection of such factor interactions [18]. However, the displayed factor interaction is not suitable for intraoperative decision making regarding the extent of surgery due to the circumstance that histopathogical results verifying microscopic venous invasion are rarely available pre- or intraoperatively. Instead the prognostic value of venous invasion in patients undergoing extended surgery should be considered within the postoperative therapeutic strategy.

Partial portal vein resection due to macroscopic tumor invasion had no statistically significant influence on survival in Cox regression analysis (Table 2) in this study while several studies described poor survival for patients
after portal vein resection, although only Miura et al. were able to show significant influence on survival in multivariable analysis [28, 31, 32]. This discrepancy could be due to the small number of cases in this study since a tendency towards worse survival in patients after partial portal vein resection has been observed. The benefit of portal vein resection therefore remains unclear.

Intraoperative frozen sections were crucial for flexible intraoperative decision making on the extent of resection, achieving tumor-free resection margins and partially led to an extension of the surgical strategy including partial portal vein, additional liver or perihilar bile duct resection. This is emphasized by the fact that the preoperative CT scans in the displayed cohort were not a reliable predictor of tumor extent. CT scans of 22 patients identified no measurable tumor mass although final histology revealed tumor sizes between T stage 1 and 4 in these patients. Even additional MR tomography did not provide significantly better results in preoperative detection of tumor extent. Therefore, in some cases endosonography might help for identification of tumor extent.

Finally patients with stricture of the distal bile duct suspicious of a malignant tumor should be explored surgically even if histology was negative, since 49.3% of preoperative histologies were false negative.

The impact of positive tumor infiltration at the surgical resection margin (R1/2 resection) on postoperative survival following curative resection of DCCs is widely discussed. We found no significant impact of R1/2 resection on overall survival in Cox regression analysis (Table 2). This finding is in line with some of the published series [15, 33–35]. Other studies identified positive resection margins as an independent prognostic factor on overall survival [3, 28]. Interestingly the percentage of R1 or R2 resected patients differs widely between the aforementioned published series from 7.0 to 43.3% [3, 15, 28, 33–37]. Our series shows a comparatively low rate of R1/R2 resections with 13.3%. A comparable retrospective study with 10.5% positive resections margins found no significant difference in survival for these patients in uni- and multivariable analysis [15]. Two published series found rates of 13.4 and 14.0% of R1/2 resected patients, respectively with significant influence on patient survival in uni- but not in multivariable analysis [33, 35]. In contrast series with higher rates of cancer positive resection margins identified R1/2 resections as an independent significant negative prognostic factor on survival in multivariable analysis [28, 38]. This could implicate a correlation of higher rates of positive resection margins with the identification of R1/2 resections as a significant negative prognostic factor in multivariable analysis in some series, which in turn would explain the conflicting results of our and these series [15, 33–35]. As displayed above, further local or extended resection in case of initially positive intraoperative resection margins was performed on a regular basis especially in patients undergoing local excision of bile duct and did not impact recurrence rate or overall survival. Interestingly there is presently no further data on this matter in patients undergoing resection for distal cholangiocarcinoma. Until further clarification the primary goal of surgical resection of DCC should be to achieve R0 resection. We therefore recommend intraoperative frozen sections of the resection margins and when residual disease is detected, additional resection of the bile duct bifurcation or locally infiltrated structures should be performed if technically feasible.

The presence of tumor positive lymph nodes was identified as a significant prognostic factor in multivariable analysis (Table 2) as was reported by different meta-analysis and some multicenter studies [28, 30, 36, 38]. Apart from a German study by Petrova et al., all mentioned publications reported a significant impact of lymph node metastasis on survival in uni- and not in multivariable analysis [28]. The above mentioned German colleagues did not report on the impact of the number of metastatic lymph nodes on survival. This seems to be relevant as Kiriyama et al. demonstrated earlier that the total number of infiltrated lymph nodes influences patients outcome. They found a significant difference when comparing no lymph node metastasis with 1–3 and more than 4 metastases [39]. This correlates well with our findings, as we classified the number of lymph node metastasis according to the newest TNM 8th edition classification for DCC in N0 versus N1 (1–3 positive lymph nodes) versus N2 (≥ 4 positive lymph nodes) resulting in a negative prognostic factor for each grade with a hazard ratio of 2.18 in multivariable analysis.

Postoperative complications graded in points according to Clavien-Dindo had a significant impact on patient outcome (Table 2). The influence of postoperative morbidity on the outcome of patients with DCC was recently observed by Petrova et al. and Andrianello et al. Aside from direct consequences leading to early death in hospital it is assumed that patients with complicated postoperative course experience delay in the start of adjuvant therapy options (i.e. chemotherapy) resulting in an inferior survival [28, 40]. However the efficiency of adjuvant chemotherapy in patients with cholangiocarcinoma, as currently investigated by the multicenter prospective ACTICCA trial, remains unclear [41].

**Conclusion**

Preoperative biliary stenting, positive lymph node staging, perineural invasion as well as extended surgery in patients with concomitant venous invasion and postoperative complications should be considered within the
peroperative therapeutic strategy. It is important to state that it is difficult to draw definite conclusions from this retrospective study considering the small patient collective undergoing extended surgery, respectively. Therefore it would certainly be beneficial performing multi-center studies with prospective analysis to determine which surgical approach is justifiable regarding optimal patient outcome. In addition the effects of preoperative biliary drainage in patients with DCC and relevant cholestasis on survival should be thoroughly examined in respect of our presented data.

Abbreviations
DCC: Cholangiocarcinoma; EVG: Elastic Van Gieson’s; HE: Haematoxylin and eosin; HR: Hazard ratio; ICU: Intensive care unit; OR: Odds ratio; OS: Overall survival; PAS: Periodic acid–Schiff; PTFE: Polytetrafluoroethylene

Funding
There is no funding for the present study.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
Study conception and design: OB, HS, FV, MoK. Acquisition of data: OB, MIK, HS, MoK, KJO. Analysis and interpretation of data: OB, HS, JG, MoK, KJO. Drafting of manuscript: OB, MIK, HS, MoK, KJO. Critical revision of manuscript: HS, MoK, KJO. Analysis and interpretation of data: OB, HS, JG, MoK, KJO. Study conception and design: OB, HS, FV, MoK. Acquisition of data: OB, MIK, HS, MoK, KJO. Critical revision of manuscript: HS, JG, FV, SC, FO, JK. All authors have read and approved the final version of this manuscript.

Ethics approval and consent to participate
According to the Professional Code of the German Medical Association (article B.III. § 15.1) neither informed consent nor approval of an ethics committee was needed. Nonetheless patients provided informed consent that their data may be used for scientific purposes at the time of hospital admission which is the general policy of our institution. The ethical committee of hannover Medical School further stated that no approval is needed. Patient records and patient data were anonymized and de-identified prior to analysis.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of General, Visceral and Transplant Surgery, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. 2Core Facility Quality Management Transplantation, Integrated Research and Treatment Center Transplantation (IFB-Tx), Hannover Medical School, Hannover, Germany. 3Department of General, Visceral and Oncological Surgery, Asklepios Klinik Barmbek, Hamburg, Germany.

Received: 2 April 2018 Accepted: 26 July 2018

Published online: 13 August 2018

References
1. Bragazzi M, Cardinale V, Carpino G, Venere R, Semeraro R, Gentile R, Gaudino E, Alvare D. Cholangiocarcinoma: epidemiology and risk factors. Translational Gastrointestinal Cancer. 2011;1:21–32.
2. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Plantaditis S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463–73. discussion 473-5
3. De Oliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755–62.
4. Keymolen K, Delsemme A, Schmitz G, Geerts A, Nuyts S, De Kock J. The impact of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg. 1999;229:76–83.
5. Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery. 2005;137:396–402.
6. Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg. 2005;241:77–84.
7. Sasaki R, Takeda Y, Funato O, Nitta H, Kawamura H, Uesugi N, et al. Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma. World J Surg. 2007;31:1788–96.
8. Bahra M, Jacob D, Langrehr JM, Neumann UP, Neuhaus P. Carcinoma of the distal and middle bile duct: surgical results, prognostic factors, and long-term follow-up. J Hepato-Biliary-Pancreat Surg. 2008;15:501–7.
9. Todoroki T, Kawamoto T, Kokie N, Fukao K, Shoda J, Takahashi H. Treatment strategy for patients with middle and lower third bile duct cancer. Br J Surg. 2001;88:364–70.
10. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.
11. Yoshida T, Matsumoto T, Sasaki A, Morii Y, Aramaki M, Kitano S. Prognostic factors after pancreatectoduodenectomy for extended lymphadenectomy for distal bile duct cancer. Arch Surg, 2002;137:69–73.
12. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Orge H, Sueda T. Pancreatectoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis. World J Surg. 2007;31:337-42. discussion 343-4
13. Lee HG, Lee SH, Yoo DD, Paik KY, Heo JS, Choi SH, et al. Carcinoma of the middle bile duct: is bile duct segmental resection appropriate? World J Gastroenterol. 2009;15:5966–71.
14. Wakai T, Shirai Y, Tsuichya Y, Nomura T, Akazawa K, Hatakeyama K. Combined major hepatectomy and pancreatectoduodenectomy for locally advanced biliary carcinoma: long-term results. World J Surg. 2008;32:1067–74.
15. Ebata T, Nagino M, Nishio H, Iga M, Tokuoka Y, Yokoyama Y, Nimura Y. Pancreatic and duodenal invasion in bile duct bile cancer: paradox in the tumor classification of the American joint committee on Cancer. World J Surg. 2007;31:2008–15.
16. Willberger G, Renzien F, Benzing C, Atanasov G, Klein F, Hau HM, et al. Prognostic accuracy of the seventh edition of the TNM classification compared with the fifth and sixth edition for distal Cholangiocarcinoma. Ann Surg Oncol. 2016;23:1320–6.
17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
18. Hosmer DW, Lemeshow S, May S. Applied survival analysis: regression modeling of time to event data. 2nd ed. New York: Wiley-Interscience; 2008.
19. Gwiasda J, Schulte A, Kaltenborn A, Ramackers W, Kleine M, Beetz O, et al. Identification of the resection severity index as a significant independent prognostic factor for early mortality and observed survival >5 and >10 years after liver resection for hepatocellular carcinoma. Surg Oncol. 2017;26:178–87.
20. van der Gaag NA, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Zuidema GD, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362:1279–32.
21. Rodarte-Shade M, Kahaleh M. Stent placement as a bridge to surgery in malignant biliary obstruction (pancreatic cancer, distal bile duct cancer, and hilar tumors). Gastrointestinal Intervention. 2015;4:21–6.
22. Fong Y, Blumgart LH, Lin E, Fordt IG, Brennan MF. Outcome of treatment for distal bile duct cancer. Br J Surg. 1996;83:1712–5.
23. Zerbi A, Balzano G, Leone BE, Angeli E, Veronesi P, Di Carlo V. Clinical presentation, diagnosis and survival of resected distal bile duct cancer. Dig Surg. 1998;15:410–6.
24. Allen PJ, Reiner AS, Gonen M, Klimstra DK, Blumgart LH, Brennan MF, et al. Extrahepatic cholangiocarcinoma: a comparison of patients with resected proximal and distal lesions. HPB (Oxford). 2008;10:341–6.
25. Hatzaras I, George N, Muscarella P, Melvin WS, Ellison EC, Bloomston M. Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol. 2010;17:991–7.
26. Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK, Kim YT, et al. Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol. 2007;14:3195–201.
27. Chung YJ, Choi DW, Choi SH, Heo JS, Kim DH. Prognostic factors following surgical resection of distal bile duct cancer. J Korean Surg Soc. 2013;85:212–8.
28. Petrova E, Ruckert F, Zach S, Shen Y, Weitz J, Grutzmann R, et al. Survival outcome and prognostic factors after pancreatectoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study. Langenbeck’s Arch Surg. 2017;402:831–40.
29. Courtin-Tanguy L, Rayar M, Bergeat D, Mendrignac A, Hamoy Y, Boudjema K, et al. The true prognosis of resected distal cholangiocarcinoma. J Surg Oncol. 2016;113:575–80.
30. Zhou Y, Liu S, Wu L, Wan T. Survival after surgical resection of distal cholangiocarcinoma: a systematic review and meta-analysis of prognostic factors. Asian J Surg. 2017;40:29–38.
31. Miura F, Sano K, Armano H, Toyota N, Wada K, Yoshida M, et al. Evaluation of portal vein invasion of distal cholangiocarcinoma as borderline resectability. J Hepatobiliary Pancreat Sci. 2015;22:294–300.
32. Maeta T, Ebata T, Hayashi E, Kawahara T, Mizuno S, Matsumoto N, et al. Pancreaticoduodenectomy with portal vein resection for distal cholangiocarcinoma. Br J Surg. 2017;104:1549–57.
33. Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Distal bile duct carcinoma: prognostic factors after curative surgery. A series of 112 cases. Ann Surg Oncol. 2007;14:1212–9.
34. Hernandez J, Cowgill SM, Al-Saadi S, Villadolid D, Ross S, Kraemer E, et al. An aggressive approach to extrahepatic cholangiocarcinomas is warranted: margin status does not impact survival after resection. Ann Surg Oncol. 2008;15:807–14.
35. Qiao QL, Zhang TP, Guo JC, Zhan HX, Zhao JX, Liu YC, et al. Prognostic factors after pancreatectoduodenectomy for distal bile duct cancer. Am Surg. 2011;77:1445–8.
37. Iso Y, Kita J, Kato M, Shimoda M, Kubota K. When hepatic-side ductal margin is positive in N+ cases, additional resection of the bile duct is not necessary to render the negative hepatic-side ductal margin during surgery for extrahepatic bile duct carcinoma. Med Sci Monit. 2014;20:471–5.
38. Wellner UF, Shen Y, Keck T, Jin W, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surg Today. 2017;47:271–9.
39. Kitayama M, Ebata T, Aoba T, Kaneoka Y, Arai T, Shimizu Y, et al. Prognostic impact of lymph node metastasis in distal cholangiocarcinoma. Br J Surg. 2015;102:399–406.
40. Andrianello S, Marchegiani G, Mallego G, Rusev BC, Scarpa A, Bonaminì D, et al. Over 700 Whipples for Pancreaticobiliary malignancies: postoperative morbidity is an additional negative prognostic factor for distal bile duct cancer. J Gastrointest Surg. 2017;21:527–33.
41. Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klumpen HJ, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015;15:564,015–1498-0.